BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare CNS: Attention Deficit Hyperactivity Disorder (ADHD) Market Spotlight

February 17, 2021

Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders, affecting approximately 2.2–7.2% of children and adolescents, and 2.8–5.0% of adults globally. The condition is characterized by persistent inattention, hyperactivity, and/or impulsive behavior that is more severe and more frequent than that typically observed in individuals of a similar developmental stage. This results in functional impairment in areas such as cognition, social interaction, employment, self-care, and mobility. The disorder is often diagnosed in early childhood, although recent studies have highlighted the potential for late-onset and even adult-onset ADHD. Due to its high prevalence, strong correlation with subsequent psychiatric co-morbidities, persistence into adulthood, and functional impairment across the life course, ADHD is now being recognized as an important disorder worldwide.

This Datamonitor Healthcare report contains a Market Spotlight module.

Indications Covered: Attention Deficit Hyperactivity Disorder (ADHD)
Back to the top Back to the top